AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03895671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Induction phase (first three cycles)~- ponatinib: 45 mg/day orally continuously~Following the results of disease evaluation after 3 cycles:~* Cohort A: AP-CML If a CHR and complete cytogenetic response are obtained after 3 months, ponatinib will be decreased at 30mg/day. If CHR and/or CCyR are not reached, ponatinib may be maintained at 45mg/day for another 3 cycles if decided by the investigator.~* Cohort B: MBC-CML If a CHR is obtained during the induction phase, ponatinib daily dose will be reduced to 30 mg/day. If CHR is not reached, ponatinib may be maintained at 45mg/day for another 3 cycles if decided by the investigator.~Maintenance therapy:~Ponatinib will be decreased to 30 mg/day. During maintenance therapy, If a major molecular response is reached, ponatinib will be decreased to 15mg/day
Study NCT03895671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Induction phase (first three cycles), Following the results of disease evaluation after 3 cycles and Maintenance therapy:~- 5-azacitidine : 75 mg/m² subcutaneously day 1 to day 7, every 4 weeks~No dose modification of 5-Azacitidine is planned in both cohorts. Azacitidine may be stopped at 24 months in case of MR4 defined as 0.0032%\<MR4≤0.01%;
Study NCT03669939 — intervention group
Intervention type: OTHER
Intervention: Communication Strategy
Description: Communication Strategy The intervention consists of a handbook that refers to the CDC Guidelines with tools and communication strategies that the PCP can use when assessing their patients who are on opioids. The Handbook will have a description of the Ohm-app and the information the PCP can retrieve from the dashboard in their medical record. They will also be provided a template to use when seeing the patient to use as guide and as documentation.
Study NCT03669939 — intervention group
Intervention type: OTHER
Intervention: Standard of Care
Description: The standard information about the CDC Guidelines and no other information that is available through the study.
Study NCT05003778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction training
Description: Participants will undergo 6 weeks of blood flow restriction training
Study NCT02280148 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy of Intravenous Anesthesia
Description: The dose of intravenous anesthesia drug and time was controlled by the anesthesiologist,endoscopists were responsible for gastroscopy or colonoscopy , nurses assisted endoscopists with biopsy.Each subject's initial dose of propofol were set at 2mg / kg, and were added properly by anesthesiologists additional according to the subjects' intraoperative sedation or surgical time.
Study NCT02257242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 90 mg/m2 I.V. on Day 1 and 2 of each cycle
Study NCT02257242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine sulfate liposome injection
Description: Dose per dose escalation protocol, I.V. on Day 2 of each cycle
Study NCT03216720 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG
Description: * Cannulation: 24-F arterial cannula, 29/29 F dual-stage venous cannula, and aortic root vent-/cardioplegia cannula~* Grafting: pedicled left internal mammary artery, and no-touch~* saphenous vein graft Heparin and protamine doses assessed by HMS Plus® Hemostasis Management System~* Target activated coagulation time of >400 seconds
Study NCT03216720 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Miniaturized extracorporeal circulation
Description: * Centrifugal pump to reduce mechanical stress~* Circuit coated with biosurface to increase haemocompatibilty.~* Ante- and retrograde autologous priming and low-volume cardioplegia solution (intermittend cold modified Calafiore) to minimize haemodilution~* Collapsible soft-shell reservoir for blood volume management~* Cell-saving device~* Venous air removing device and electric clamp system to air embolism
Study NCT03216720 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional extracorporeal circulation
Description: * Roller pump~* Circuit uncoated~* Hard-shell venous reservoir~* Intermittend cold blood Harefield cardioplegia
Study NCT04130893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stimulation of G13 then G15
Description: Study participant randomized into arm A will undergo a stimulation of point G13 at session N°2, then stimulation of point G15 at session N°3.
Study NCT04130893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stimulation of G15 then G13
Description: Study participant randomized into arm B will undergo a stimulation of point G15 at session N°2, then stimulation of point G13 at session N°3.
Study NCT02649452 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: vibration
Description: vibration will be given using whole body vibration machine. The subject will place both palms on top of the vibration platform with their knee supported on the ground. They need to apply as much pressure on the vibration platform by using their body weight. The whole body vibration machine will be set at the frequency of 30 Hz and the amplitude of 5 mm. They need to hold that position for 1 minute for 3 sets with 1 minute rest in between. The researcher will immediately stop this if the subjects feel dizziness and discomfort
Study NCT02649452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vibration
Description: vibration will be given using whole body vibration machine. The subject will place both palms on top of the vibration platform with their knee supported on the ground. They need to apply as much pressure on the vibration platform by using their body weight. The whole body vibration machine will be set at the frequency of 30 Hz and the amplitude of 5 mm. They need to hold that position for 1 minute for 3 sets with 1 minute rest in between. The researcher will immediately stop this if the subjects feel dizziness and discomfort
Study NCT01030120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept
Description: etanercept 50mg BIW S.Q.
Study NCT01030120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01125410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dequalinium chloride
Description: Vaginal tablet, 10mg, 1 tablet daily for 6 days
Study NCT01125410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: vaginal cream, 2%, once daily for 7 days
Study NCT01242631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 10 mg orally per day.
Study NCT05026151 — intervention group
Intervention type: OTHER
Intervention: Nutrition therapy according to ICU protocol
Description: The study aims a verifying adherence to the ICU nutrition protocol
Study NCT00276406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Description: Pyridostigmine will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
Study NCT00276406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: If subject is randomized to placebo, placebo pills will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
Study NCT01356862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PASIREOTIDE
Description: One INTRAMUSCULAR INECTION OF PASIREOTIDE 60 MG 10 TO 7 DAYS BEFORE SURGERY
Study NCT01356862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: ONE INJECTION OF PLACEBO 10 TO 7 DAYS BEFORE SURGERY
Study NCT00682279 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: oral topotecan (SK&F-104864); lapatinib (GW572016)
Description: This is a single-arm, dose escalation, Phase I study in which doses of oral topotecan will be escalated and lapatinib will be given initially as a fixed dose. This study will examine oral topotecan administered on a five-consecutive day schedule in combination with daily lapatinib. This study will be conducted in two parts. Part 1 of the study will investigate the impact of lapatinib on the bioavailability of oral topotecan (bioavailability phase) and Part 2 of the study will consist of dose finding to determine the MTD regimen of the combination (dose escalation phase).
Study NCT02521857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Sublingual tablet administered followed by consumption of 240 mL (8 ounces) of water at different timepoints
Study NCT02908633 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: canaloplasty and phacoemulsification
Study NCT03174626 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WLSCC
Description: Briefly, WLSCC contents are as follows: Psychosocial skill 1: Increase objectivity and awareness of thoughts and feelings in a distressing situation and learning the technique of a log entry; Psychosocial skill 2: Evaluate the situation to decide whether to change one's reactions or to take actions; Psychosocial skill 3: Increase the positive and the sense of meaning in your life; Psychosocial skill 4: Deflection strategies; Psychosocial skill 5: Take action when action is called for; Psychosocial skill 6: Assertion; Psychosocial skill 7: Saying No; Psychosocial skill 8 : Communication; Psychosocial skill 9: Become a better listener; Psychosocial skill 10: Empathy.
Study NCT03174626 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: No training provided. After data collection period is over, participants have the option to receive the WLSCC training
Study NCT02449811 — intervention group
Intervention type: DRUG
Intervention: Perindopril
Study NCT02449811 — intervention group
Intervention type: DRUG
Intervention: Olmesartan
Study NCT02449811 — intervention group
Intervention type: DRUG
Intervention: Amlodipine
Study NCT02449811 — intervention group
Intervention type: DRUG
Intervention: Hydrochlorothiazide
Study NCT00740753 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Yttrium 90 (TheraSphere)
Description: Y-90 embedded glass microspheres
Study NCT01741298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHARMS
Description: Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
Study NCT03633656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Model predictive control
Description: Computer aided dose selection for the treatment of iron deficient anemia.
Study NCT02280148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Driving Simulator
Study NCT02280148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 2mg / kg
Study NCT02300675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: therapeutic education program
Study NCT01205048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emervel Classic Lidocaine
Description: 20 mg/mL + 0.3% lidocaine
Study NCT01205048 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvederm® Ultra
Description: 24mg/mL
Study NCT03942237 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single-injection QLB(quadratus lumborum block)
Description: Inject 0.4ml/kg 0.5% ropivacaine between quadratus lumborum and psoas major muscle~Device: The curved (C1-5) probe of Ultrasound Scanner Philips CX50 is used for scan~Drug: single dose ropivacaine 0.4ml/kg 0.5% ropivacaine is given immediately after the correct position of needle tip is verified.
Study NCT03942237 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Inject 0.4ml/kg saline between quadratus lumborum and psoas major muscle~Device: The curved (C1-5) probe of Ultrasound Scanner Philips CX50 is used for scan~Drug: single dose 0.4ml/kg 0.9% NS is given immediately after the correct position of the needle tip is verified
Study NCT04258007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Reversal Neostigmine
Description: Patients will receive 0.02 mg/ kg atropine and 0.04 mg/ kg neostigmine following observing the second response on stimulating the ulnar nerve on the TOF watch
Study NCT04258007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reversal Sugammadex
Description: Interventional Arm Patients undergoing cardiac catheterization will receive sugammadex 4 mg/ kg when the T2 is observed on the TOF watch
Study NCT02481596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACH + FAMS
Description: The intervention consists of REACH individual-focused text messaging, plus family-focused phone coaching sessions, goal-focused text messaging, and the option to invite a family member/support person to receive text messages.
Study NCT02481596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACH
Description: The intervention consists of daily text messaging tailored to user's individual barriers to medication adherence, plus text messaging targeting other self-care behaviors (see NCT02409329).
Study NCT02481596 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Helpline & A1c results
Description: Participants complete all study assessments, receive text messages advising how to access study A1c results, and have access to a helpline for study- or diabetes medication-related questions.
Study NCT02481596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Helpline & A1c results
Description: Participants complete all study assessments, receive text messages advising how to access study A1c results, and have access to a helpline for study- or diabetes medication-related questions.
Study NCT02131246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Subjects will receive a single dose of either Faster-acting insulin aspart or NovoRapid® at a predefined fixed dose level in connection to intake of a standardised meal. Administered subcutaneously (s.c., under the skin)
Study NCT03185650 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: tPAD Device
Description: A novel, transnasal aerosol generator
Study NCT03185650 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PARI LC Star Nebulizer
Description: Standard oral nebulizer
Study NCT01989741 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sleep restriction
Description: 4 hours sleep by night during one week
Study NCT00848887 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted and un-adjuvanted influenza vaccines
Description: 16 different formulations of trivalent influenza vaccine and 1 marketed influenza vaccine comparator.
Study NCT03967535 — intervention group
Intervention type: DEVICE
Intervention: MRI Brain Imaging
Description: Up to two Magnetic Resonance Imaging (MRI) scan sessions will be done, altogether totaling just under 3 hours of scanning. MR scanners measure brain anatomy and activity using very strong magnets. No X-rays or radiation are involved.
Study NCT03967535 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mental Health Assessment and Computerized Cognitive Test
Description: Participants will be asked to complete questionnaires and will be asked questions that address a broad range of personal life experiences involving social, occupational, domestic, and other behaviors.
Study NCT04390295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once daily, 24 weeks
Study NCT04390295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824
Description: Once daily, 52 weeks
Study NCT04390295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Three times daily, 52 weeks
Study NCT03481816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-071; adenoviral PSA vaccine
Description: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.
Study NCT02789553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: First starch meal then meal with glucose syrup
Description: Before bypass surgery, patients will take randomized meal. One day a starch meal and another day a glucose syrup meal. 3 months after surgery, they will take these 2 randomized meal again, one day the first one, and the day after the other one.
Study NCT02789553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: First meal with glucose syrup then starch meal
Description: Before bypass surgery, patients will take randomized meal. One day a meal with glucose syrup and another day a starch meal. 3 months after surgery, they will take these 2 randomized meal again, one day the first one, and the day after the other one.
Study NCT03468595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasonic (Piezon Master 700) performed with Listerine
Study NCT03468595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasonic (Piezon Master 700) performed with CHX
Study NCT03468595 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonic (Piezon Master 700) performed with serum
Study NCT00485420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet based disease management program
Description: Usual Care is augmented with internet-based education, self-monitoring and clinician monitoring
Study NCT00485420 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet based disease management program
Description: Usual Care is augmented with internet-based education, self-monitoring and clinician monitoring
Study NCT00439595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemocue 210 meter
Description: Diagnostic device
Study NCT00439595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Copack HBCS
Study NCT01034501 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham procedure
Description: non activated laser tip
Study NCT01034501 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: photodynamic therapy
Description: photodynamic therapy 660 nm,40 mW,60 Hz
Study NCT02708316 — intervention group
Intervention type: GENETIC
Intervention: sequencing faecal metagenome
Description: sequencing faecal metagenome is not the intervention measure.It is the observational method for investigators to detect the component of faecal microorganism.
Study NCT02649920 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical ripening balloon
Study NCT02649920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone
Study NCT00595296 — intervention group
Intervention type: DEVICE
Intervention: GeneSearch™ Breast Lymph Node (BLN) Assay
Description: The GeneSearch™ BLN Assay is a real time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay that detects the presence of breast tumor cell metastasis in lymph nodes through the detection of gene expression markers present in breast tissue, but not in nodal tissue (cell type specific messenger RNA).
Study NCT03930381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASTHMAXcel App
Description: ASTHMAXcel includes interactive games, educational videos, quizzes and personalized feedback to teach different aspects of asthma management.
Study NCT03551834 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional scleral patch graft glaucoma implantation
Description: conventional AGV implantation by using scleral patch graft to cover the tube and prevent tube exposure
Study NCT03551834 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: New surgical method (short tunnel small flap technique)
Description: a novel technique named short tunnel small flap (STSF) by tunneling the sclera to pass the AGV tube without using scleral patch graft.
Study NCT01367379 — intervention group
Intervention type: PROCEDURE
Intervention: 24 hour EKG and blood pressure monitor
Description: All subjects will have non-invasive 24 hour EKG and 24 hour EKG monitoring for 24 hours.
Study NCT01367379 — intervention group
Intervention type: OTHER
Intervention: Blood and urine sampling
Description: Right before and after the duty loading, all subjects will have blood samplings, including CRP, WBC, IL-6, Fibrinogen, insulin, IL-6, Procalcitonin, TNF-alfa, catecholamine level. Right after the duty loading, all subjects will have urine samplings for cortisol and catecholamine level.(blood : 15CC/time and 2\~4 times/month)
Study NCT03326635 — intervention group
Intervention type: OTHER
Intervention: Frailty in elderly (≥70 y) patients in ICU
Description: Determine the prevalence of frailty in elderly patients (≥ 70 year old) in a group of French ICUs. The frailty is measured by a score (Fried score) at the admission of the patient
Study NCT00481455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panzem NCD
Description: 2000 mg q8h, continuous dosing in 28 day cycles
Study NCT00481455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Fixed dose
Study NCT03041324 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB-913
Description: Single dose of each of the 3 components of SB-913: ZFN1, ZFN2 and hIDS Donor